Alkermes PLC (NASDAQ:ALKS) Price Target Cut to $66.00

Alkermes PLC (NASDAQ:ALKS) had its target price dropped by equities research analysts at Credit Suisse Group from $70.00 to $66.00 in a note issued to investors on Friday, October 27th. The brokerage currently has an “outperform” rating on the stock. Credit Suisse Group’s price target points to a potential upside of 38.39% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on ALKS. J P Morgan Chase & Co set a $78.00 target price on Alkermes PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. BidaskClub cut Alkermes PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. ValuEngine cut Alkermes PLC from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Barclays PLC cut Alkermes PLC from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $66.00 to $50.00 in a research note on Monday, October 16th. Finally, Jefferies Group LLC set a $69.00 price target on Alkermes PLC and gave the company a “buy” rating in a research note on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. Alkermes PLC has a consensus rating of “Hold” and an average price target of $63.55.

Alkermes PLC (ALKS) traded down $1.48 during trading hours on Friday, hitting $47.69. The stock had a trading volume of 1,157,600 shares, compared to its average volume of 832,980. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23. Alkermes PLC has a 1 year low of $46.80 and a 1 year high of $63.40.

Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. Alkermes PLC had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company had revenue of $217.40 million during the quarter, compared to analysts’ expectations of $231.29 million. During the same quarter in the previous year, the firm earned ($0.09) EPS. Alkermes PLC’s revenue was up 20.6% on a year-over-year basis. research analysts expect that Alkermes PLC will post -0.59 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was posted by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/alkermes-plc-alks-pt-lowered-to-66-00-at-credit-suisse-group/1740756.html.

In related news, CAO Kathryn L. Biberstein sold 13,566 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the sale, the chief accounting officer now directly owns 70,455 shares of the company’s stock, valued at $3,613,636.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard F. Pops sold 50,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. Insiders sold 102,498 shares of company stock worth $5,018,010 in the last 90 days. Corporate insiders own 5.34% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank increased its position in Alkermes PLC by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after buying an additional 212 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Alkermes PLC in the third quarter worth $126,000. Daiwa SB Investments Ltd. purchased a new stake in Alkermes PLC in the second quarter worth $166,000. Virtu Financial LLC purchased a new stake in Alkermes PLC in the third quarter worth $201,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Alkermes PLC in the third quarter worth $214,000. 98.11% of the stock is owned by institutional investors and hedge funds.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Analyst Recommendations for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.